BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21087932)

  • 1. Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.
    Duan L; Motchoulski N; Danzer B; Davidovich I; Shariat-Madar Z; Levenson VV
    J Biol Chem; 2011 Jan; 286(4):2864-76. PubMed ID: 21087932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.
    Duan L; Danzer B; Levenson VV; Maki CG
    Cancer Lett; 2014 Oct; 353(2):290-300. PubMed ID: 25069039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.
    Duan L; Calhoun SJ; Perez RE; Macias V; Mir F; Gattuso P; Maki CG
    Cancer Biol Ther; 2022 Dec; 23(1):1-10. PubMed ID: 36332175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
    Wang L; Zhang X; Wang ZY
    Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
    Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
    Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
    Yang S; Lee JY; Hur H; Oh JH; Kim MH
    BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
    Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
    Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
    Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
    Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
    Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
    J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
    Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
    Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.